Peer Reviewed
Drug update

Reuptake inhibitors for depression

Bill Lyndon
An updated version is available in the linked supplement
Abstract

The newer neurotransmitter reuptake inhibitors, because of their greater selectivity, have significant advantages in safety and side effects compared with the original reuptake inhibitors, the tricyclics.

Key Points

    The management of depression advanced greatly with the development of antidepressant agents based on neurotransmitter reuptake inhibition and, more recently, the development of reuptake inhibitors selective for specific neurotransmitters. These newer antidepressants have fewer side effects and less toxicity than the older agents. The pharmacology of the reuptake inhibitors, and particularly the newer drugs, is discussed in this article.

Get full access
Subscribe for full access to all articles
Buy this article

Single article purchases are temporarily unavailable due to site maintenance.

If you would like to purchase an article during this time, please email us at [email protected] with the article details and we'll assist you directly. We'll also let you know when online purchasing is available again.

Thank you for your patience and understanding.

Already a subscriber?